2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 468

Adalimumab Treatment Is Associated with Decreased Concomitant Rheumatoid Arthritis Medication Use Over 24 Months
Abstract Number: 16

Adenosine A_2A Receptor Diminishes Bone Destruction At Inflamed Sites, in Part, Via Downregulating Semaphorin4D-PlexinB1 Communication Between Osteoclasts and Osteoblasts
Abstract Number: 15

Adenosine A_2A Receptor Stimulation Inhibits OC Formation by Suppressing NFkB Translocation to the Nucleus by A PKA-ERK1/2 Mediated Mechanism
Abstract Number: 1778

Adenosine A2A Receptor (A_2AR) Activation Stimulates Increased Expression of Collagen-1 and Collagen-3 by Different Signaling Pathways in Normal Human Dermal Fibroblasts
Abstract Number: 2516

Adenosine Receptors Stimulate Bone Regeneration by Targeting Osteoclasts
Abstract Number: 1965

Adenosine Regulates Bone Metabolism Via A₁, A_2A and A_2B Receptors in Bone Marrow Cells From Normal and Patients with Multiple Myeloma
Abstract Number: 2607

Adherence to a Treat-to-Target Strategy in Early Rheumatoid Arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort
Abstract Number: 634

Adherence to Adult Treatment Panel III Guidelines for Systemic Lupus Patients
Abstract Number: 2289

Adiponectin Has Potent Anti-Fibrotic Effects Mediated Via AMP Kinase: Novel Target for Fibrosis Therap
Abstract Number: 2097

Adiponectin Is Associated with Pro-Inflammatory Cytokines in Autoantibody Positive First-Degree Relatives (FDRs) of Patients with Rheumatoid Arthritis
Abstract Number: 705

Adipose Derived Stem Cells As an Alternative Source of Cellular Repair for Vascular Dysfunction in Systemic Sclerosis
Abstract Number: 260

Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program
Abstract Number: 647

Adjusted Framingham Risk Factor Scoring for Systemic Lupus Erythematosus: Results from an Inception Cohort Followed for Eight Years
Abstract Number: 2010

Administration of Routine Preventative Vaccinations in Children with Juvenile Idiopathic Arthritis Receiving Adalimumab
Abstract Number: 1150

Adverse Events in Juvenile Idiopathic Arthritis: Results From the Enhanced Drug Safety Surveillance (EDSS) Pilot Project

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].